ALK and non-small cell lung carcinoma: Currently, according to the National Comprehensive Cancer Network (NCCN) guidelines, the second-generation ALK-tyrosine kinase inhibitors (TKIs), such as alectinib and brigatinib, and the third-generation ALK-TKI, lorlatinib, are the preferred first-line treatment recommendations for patients with advanced NSCLC harboring ALK gene rearrangement, as they could achieve outstanding survival benefit from ALK inhibitor (ALKi) therapy (Ettinger et al., 2022).